Clinical Trial: NCT05246514
A Single Arm Phase 2 Study to Evaluate Efficacy and Safety of Trastuzumab Deruxtecan for Patients With HER2 Mutant NSCLC
Status:
ACTIVE NOT RECRUITINGPhase:
Phase 2| Lead Sponsor: | AstraZeneca |
| Information Provided By: | AstraZeneca |
| Last Update Posted: | 2026-08-18 |
Study Overview
Brief Summary
The purpose of this study is to evaluate the efficacy and safety of T-DXd in participants with HER2 mutant metastatic non-squamous NSCLC.
Official Title
An Open-label, Single-arm, Phase 2 Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd) for Patients With HER2-mutant Metastatic NSCLC Who Have Disease Progression on or After at Least One-line of Treatment (DESTINY-Lung05)
Conditions
HER2-mutant Non-Small Cell Lung Cancer
Intervention / Treatment
- Drug: Trastuzumab deruxtecan
Other Study ID Numbers
- D7811C00001
Start Date (Actual)
2022-07-13
Primary Completion Date (Actual)
2024-11-04
Study Completion Date (Estimated)
2026-12-31
Enrollment (Actual)
72
Study Type
Interventional
Phase
Phase 2
| Lead Sponsor: | AstraZeneca |
| Information Provided By: | AstraZeneca |
| Last Update Posted: | 2026-08-18 |
Study Overview
Brief Summary
The purpose of this study is to evaluate the efficacy and safety of T-DXd in participants with HER2 mutant metastatic non-squamous NSCLC.
Official Title
An Open-label, Single-arm, Phase 2 Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd) for Patients With HER2-mutant Metastatic NSCLC Who Have Disease Progression on or After at Least One-line of Treatment (DESTINY-Lung05)
Conditions
HER2-mutant Non-Small Cell Lung Cancer
Intervention / Treatment
- Drug: Trastuzumab deruxtecan
Other Study ID Numbers
- D7811C00001
Start Date (Actual)
2022-07-13
Primary Completion Date (Actual)
2024-11-04
Study Completion Date (Estimated)
2026-12-31
Enrollment (Actual)
72
Study Type
Interventional
Phase
Phase 2